A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)

NCT06721143 | Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: AION-301-CKD-2024
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 2

Brief Summary

The goal of this clinical trial is to learn about the safety (good or bad) of giving two AION-301 intravenous (IV) infusions, in adults with Stage 3 Chronic Kidney Disease (CKD). It will also help to learn if AION-301 reduces the symptoms of CKD and/or progression. The main questions it aims to answer are:

• Do participants have medical problems (adverse events) after receiving two infusions of AION-301?
• Do participants feel better (have reduced and/or delayed CKD symptoms)?
• To learn about how AION-301 works in participants with CKD? Researchers will compare AION-301 to a placebo (a look-alike substance that contains no drug) to see if AION-301 works to treat Stage 3 CKD. Participants will:
• Receive two infusions of AION-301 or placebo on two separate days (Day 0 and Day 4).
• Receive oral vitamins at the clinic and to take at home for 90 days.
• Visit the clinic for a minimum of 9 times, over 6 months for checkups and tests, but could be up to 12 times, over 24 months for checkups and tests.

Conditions

Chronic Kidney Disease Stage 3

Keywords

CKD; AION-301; Stage 3 CKD; Chronic Kidney Disease

Outcome Measures

Primary Outcomes (1)

• Number of Treated Participants Experiencing Grade 3 or Above Adverse Events As Assessed by CTCAE V5.0

  The primary analysis will be to test safety and tolerability AION-301 DP treatment in patients with CKD as assessed by the proportion of patients experiencing adverse events grade 3 or above (based on CTCAE version 5) by day 90 following treatment in comparison with Placebo group. This will be conducted by the unblinded trial biostatistician using standard two sample tests of proportions such as chi-squared tests or Fisher's exact tests.

  From baseline through day 90

Secondary Outcomes (4)

• To assess the potential evidence of efficacy in participants by

  From Baseline for up to 2 years

• To assess the potential evidence of efficacy in participants by

  From Baseline for up to 2 years

• To assess the potential evidence of efficacy in participants by

  From Baseline for up to 2 years

• KidneyIntelX Risk Profile

  From baseline through 6 months

Study Arms (2)

Group I

ACTIVE COMPARATOR

AION-301

Biological: AION-301

Group II

PLACEBO COMPARATOR

Placebo

Drug: Placebo

Interventions

AION-301 BIOLOGICAL

AION-301 Infusion

Group I

Placebo DRUG

Placebo Infusion

Group II

Eligibility Criteria

• Age: 35 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants are eligible to be included in the study only if all of the following criteria apply:
• Patient is able to communicate well with the investigator, is capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, understands all requirements of the study, and understands and signs the written ICF before any study-specific procedure.
• Willing and able to comply with the scheduled visits and treatment plan.
• Either biological sex
• Participant must be 35 to 75 years of age inclusive, at the time of signing the informed consent.
• Diagnosis of CKD stage 3, G3 (a and b): persistent eGFR between 30 and 59 mL/min/1.73 m² (at least 2 measures within that range in the preceding 3 months, including the one at screening visit), and persistent increased Albuminuria (at least 2 measures within 3 months, including 1 before screening and 1 at screening (criterion for increased Albuminuria at screening: ≥2 out of 3 repeat daily early morning samples at screening) (UACR ≥ 200 mg/g and \< than 5000 mg/g)
• Treatment with maximum labelled or tolerated dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), and SGLT2 inhibitors (SGLT2i) unless such treatment is contraindicated or not tolerated\*. Treatment dose must be stable for at least 3 months prior to the date of the screening. If a patient is on treatment with GLP-1 receptor agonist, he/she should be on a stable dose for at least 3 months before screening.
• \*Participants who are documented to be unable to take ACE inhibitors or ARBs or SGLT2i will be allowed to participate.
• Female subjects must not be breastfeeding and must have no intention to become pregnant during the study, and she will be required to use at least two FDA approved birth control during the study. The FDA-approved and cleared methods for birth control are listed below:
• Permanent Sterilization
• Long-Acting Reversible Contraceptives (LARC)
• Contraceptive Injection
• Short-Acting Hormonal Methods
• Barrier Methods
• Emergency Contraception

You may not qualify if:

• Participants are excluded from the study if any of the following criteria apply:
• Prior transplant of any organ (including BM and stem cell transplant) or kidney transplant scheduled in the next 6 months.
• Proteinuria\>5000 and or serum Albumin\< 2.5 g/dl.
• Acute coronary syndrome, stroke or TIA or hospitalization for heart failure in previous 12 weeks or poorly controlled hypertension (≥160/100 mmHg at screening visit) or SBP\<90 at screening visit.
• History of malignancy (except successfully treated squamous and basal cells skin carcinoma) within 5 years of screening.
• History of atrial fibrillation (AF, AFib).
• CKD due to genetic disorder.
• History of systemic Autoimmune diseases like T1D, SLE or CKD caused by any autoimmune kidney disease.
• Acute Kidney Injury (AKI) defined as increase in serum creatinine ≥1.5 times baseline in the previous 3 months or by presence of acute tubular injury in kidney biopsy in the previous 3 months.
• Dialysis for acute renal failure within 12 weeks of screening visit.
• Rapidly progressive kidney disease (eGFR reduction ≥ 30% over the last three months)
• HbA1c ≥ 8.5%.
• BMI ≥35 kg/m2.
• Disorder of coagulation (including any history of thrombotic or thromboembolic disease) and/or long-term anti-coagulant therapy
• History of Deep Vein Thrombosis (DVT)

Sponsors & Collaborators

• AION Healthspan, Inc.: lead
• George Clinical: collaborator

Study Sites (2)

SouthCoast Research Center, Inc.

Miami, Florida, 33136, United States

RECRUITING

University of Miami, Leonard M. Miller School of Medicine

Miami, Florida, 33136, United States

RECRUITING

MeSH Terms

Conditions

Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Giacomo Lanzoni, PHD

CONTACT

+1786-285-9512; glanzoni@aionhealthspan.com

Desa Rae E Stanton-Pastore, MS

CONTACT

+1585-305-3850; dpastore@aionhealthspan.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 7, 2024
• First Posted: December 6, 2024
• Study Start: January 23, 2025
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): May 1, 2027
• Last Updated: April 1, 2026

Record last verified: 2026-03

Locations

US (2)